

## 晚期Her-2受体阳性乳腺癌患者的临床特征及生存分析

刘俊彦<sup>1,2,3</sup>, 王哲海<sup>1</sup>

1.250117济南, 山东省肿瘤医院内科三病区;2.山东省医学科学院和济南大学;3.山东省医学科学院医学与生命科学学院

## Treatment Outcomes and Clinicopathologic Characteristics of Advanced Her-2 Positive Breast Cancer Patients

Liu Junyan<sup>1,2,3</sup>, Wang Zhehai<sup>1</sup>

1.The Third Medical Department, Shandong Tumor Hospital, Ji'nan 250117, China; 2.Academy of Medical Sciences in Shandong Province and Ji'nan University; 3.Shandong Provincial Academy of Medical Sciences and School of Medicine and Life Sciences

- 摘要
- 参考文献
- 相关文章

全文: PDF (1366 KB) HTML (1 KB) 输出: BibTeX | EndNote (RIS) 背景资料

### 摘要

#### 目的

分析晚期Her-2受体阳性乳腺癌的临床特征,探讨影响其预后的因素。方法收集本院2002年1月—2008年12月间114例晚期Her-2阳性

乳腺癌患者的临床资料,回顾性研究其临床特点、生存状况及预后因素。结果114例晚期Her-2阳性乳腺癌患者中位年龄为46岁,8例

为初治IV期;106例为初治I~III期,术后出现局部复发或远处转移。随访至2011年8月15日,死亡58例(51.0%)。单因素预后分析

结果显示,复发年龄、是否绝经、复发转移后是否接受化疗及一线化疗疗效对患者的OS有显著影响( $P<0.05$ )。Cox比例风险模型分

析结果显示,复发年龄、是否接受一线化疗以及一线化疗疗效是影响晚期Her-2高表达乳腺癌预后的独立因素。结论晚期Her-2高表

达乳腺癌患者早期易出现局部复发和远处转移,可能与其侵袭性较高有关。晚期Her-2高表达乳腺癌患者化疗能够改善其预后。

关键词: 乳腺肿瘤 预后 药物疗法 联合

### Abstract:

#### Objective

To characterize the sites of distant recurrence and clinical outcomes in a cohort of Chinese patients with metastatic Her-2 positive breast cancer. Methods One hundred and fourteen patients with metastatic Her-2 positive

breast cancer treated at Shandong Tumor Hospital from January 2002 to December 2008 were included in this study. The

clinicopathologic features and long-term survival of the patients were retrospectively analyzed. Results The median

age of the patients was 46 years. 8 patients presented with stage IV disease, 106 patients presented with I - III stage. By August 15th, 2011, 58 patients were died (51.0%). The median OS of patients with CR/PR was significantly

longer than that of patients with SD/PD. Distant metastasis, first-line chemotherapy and clinical response were significantly

related with OS by univariate analysis. Furthermore, first-line chemotherapy and clinical response were

### 服务

- ▶ 把本文推荐给朋友
- ▶ 加入我的书架
- ▶ 加入引用管理器
- ▶ E-mail Alert
- ▶ RSS

### 作者相关文章

- ▶ 刘俊彦
- ▶ 王哲海

demonstrated to be independent prognostic factor by multivariate analysis. Conclusion Recurrence risk and mortality are considerably higher in advanced Her-2 overexpressed breast cancer patients with the early years follow-up. Advanced Her-2 overexpressed breast cancer is aggressive clinical behavior. Our findings also suggest that chemotherapy can effectively improve the outcome of those patients.

Key words: Breast neoplasms Prognosis Drug therapy Combination

收稿日期: 2012-01-30;

通讯作者: 王哲海, E-mail:wzhai8778@sina.com E-mail: wzhai8778@sina.com

作者简介: 刘俊彦(1983-), 女, 硕士, 住院医师, 主要从事肿瘤内科治疗工作

引用本文:

刘俊彦,王哲海. 晚期Her-2受体阳性乳腺癌患者的临床特征及生存分析[J]. 肿瘤防治研究, 2012, 39(11): 1337-1340.

Liu Junyan, Wang Zhehai. Treatment Outcomes and Clinicopathologic Characteristics of Advanced Her-2 Positive Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2012, 39(11): 1337-1340.

没有本文参考文献

- [1] 吴涛, 王秀梅, 朱丽萍, 甫拉提, 欧江华, 倪多. 绝经后早期乳腺癌患者术后一年内发生骨密度减低的相关因素分析[J]. 肿瘤防治研究, 2013, 40(10): 966-968.
- [2] 朱通伟, 蒋天安. 声脉冲辐射力成像技术在鉴别乳腺良恶性肿瘤中的价值[J]. 肿瘤防治研究, 2013, 40(10): 972-975.
- [3] 赵海涛, 王勇, 许德志, 朱玉方, 徐军, 陶荣杰. 脑室腹腔分流加Ommaya囊置入配合化疗治疗肺癌脑膜转移的临床观察[J]. 肿瘤防治研究, 2013, 40(10): 976-979.
- [4] 王珍珍, 李珊珊, 路太英, 彭湃. 三药联合化疗方案治疗晚期非小细胞肺癌伴神经内分泌分化的疗效观察[J]. 肿瘤防治研究, 2013, 40(10): 980-983.
- [5] 黄自明, 王蓉, 薛明兴, 叶春梅, 陈波, 魏刚. 乳腺浸润性小叶癌术后卵巢转移1例报道[J]. 肿瘤防治研究, 2013, 40(10): 1011-1012.
- [6] 丁小文, 陈丰, 谢尚闹. 治疗前哨淋巴结阳性乳腺癌非前哨淋巴结状态的多因素分析[J]. 肿瘤防治研究, 2013, 40(09): 864-868.
- [7] 陈道光, 杨瑜, 陈刚, 吴君心, 肖景榕, 吴晖, 何鸿鸣, 陈英, 林剑扬, 邹思平. 107例鼻型NK/T细胞淋巴瘤临床特点和预后分析[J]. 肿瘤防治研究, 2013, 40(09): 873-876.
- [8] 谢轶群, 包家林, 徐明, 裔海鹰, 黄雷. MUC1在不同免疫表型乳腺癌组织中的强阳性表达及其与预后的关系[J]. 肿瘤防治研究, 2013, 40(08): 781-785.
- [9] 钟煜彦, 陈林. 以骨质破坏为主要表现的伯奇特(Burkitt)淋巴瘤1例报道[J]. 肿瘤防治研究, 2013, 40(08): 819-820.
- [10] 苏景伟, 祝淑钗, 王玉祥, 刘志坤, 沈文斌, 李娟. 胃泌素释放肽及其受体预测小细胞肺癌远处转移的价值分析[J]. 肿瘤防治研究, 2013, 40(07): 682-687.
- [11] 郭晓川, 张婷婷, 苏丹, 毛志远, 白莉. 小肠原发恶性肿瘤根治术后辅助化疗疗效分析[J]. 肿瘤防治研究, 2013, 40(07): 693-697.
- [12] 赵茜, 侯健. 弥漫大B细胞淋巴瘤预后相关因素研究进展[J]. 肿瘤防治研究, 2013, 40(06): 514-516.
- [13] 焦鑫, 谭志军, 孙浩, 张建良. 脂联素受体表达与II、III期结肠癌患者术后辅助化疗预后的关系[J]. 肿瘤防治研究, 2013, 40(06): 580-583.
- [14] 李嵘, 秦叔逵, 刘秀峰, 龚新雷, 华海清, 王琳. GEMOX对比GX方案一线治疗晚期转移性胆系肿瘤的临床观察[J]. 肿瘤防治研究, 2013, 40(06): 588-592.
- [15] 石宇, 王仁生, 吕君, 张婷婷, 许卓华. NO期鼻咽癌颈部可疑阳性淋巴结放疗剂量的探讨[J]. 肿瘤防治研究, 2013, 40(06): 608-612.